Revisiting nonlinear bosentan pharmacokinetics by PBPK modeling: Target binding, albeit not a major contributor to nonlinearity, can offer prediction of target occupancy

Satoshi Koyama; Kota Toshimoto; Wooin Lee; Yasunori Aoki; Yuichi Sugiyama

doi:10.1124/dmd.120.000023

OtherArticle

Revisiting nonlinear bosentan pharmacokinetics by PBPK modeling: Target binding, albeit not a major contributor to nonlinearity, can offer prediction of target occupancy

Satoshi Koyama, Kota Toshimoto, Wooin Lee, Yasunori Aoki and Yuichi Sugiyama

Drug Metabolism and Disposition February 8, 2021, DMD-AR-2020-000023; DOI: https://doi.org/10.1124/dmd.120.000023

Satoshi Koyama

1Delta Mex Inc., Japan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Satoshi Koyama

Kota Toshimoto

2Sugiyama Laboratory, RIKEN Cluster for Science, Technology and Innovation Hub, Japan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Wooin Lee

3Seoul National University, Korea, Republic of

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Wooin Lee

Yasunori Aoki

4National Institute of Informatics, Japan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Yuichi Sugiyama

5Sugiyama Laboratory, RIKEN Innovation Center, Japan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
For correspondence: ychi.sugiyama@riken.jp

Article
Figures & Data
Info & Metrics
eLetters
PDF

Submit a Response to This Article

Compose eLetter

Title *

Contents

More information about text formats

Plain text

No HTML tags allowed.
Web page addresses and e-mail addresses turn into links automatically.
Lines and paragraphs break automatically.

Author Information

Contributors
First Name and Middle Initial * First or given name, e.g. 'Peter'. Last Name * Your last, or family, name, e.g. 'MacMoody'. Email Address * Your email address, e.g. higgs-boson@gmail.com Occupation * Your role and/or occupation, e.g. 'Orthopedic Surgeon'. Affiliation * Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.

Statement of Competing Interests

Competing interests? *

Yes

Please describe the competing interests

Vertical Tabs

Jump to comment:

No eLetters have been published for this article.

PreviousNext

In this issue

Drug Metabolism and Disposition

Vol. 49, Issue 3

1 Mar 2021

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author
Editorial Board (PDF)
Front Matter (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Revisiting nonlinear bosentan pharmacokinetics by PBPK modeling: Target binding, albeit not a major contributor to nonlinearity, can offer prediction of target occupancy

Message Subject (Your Name) has forwarded a page to you from Drug Metabolism & Disposition

Message Body (Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Citation Tools

OtherArticle